Stay updated with breaking news from Cellular Therapy Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A groundbreaking phase 1 study using CAR-T cells to treat severe lupus highlights a collaborative effort between the Cellular Therapy Program and rheumatology programs to pioneer innovative patient care.
/PRNewswire/ -- The National Cord Blood Network (NCBN) proudly announces its official launch, signaling a new era of advances and collaboration in cord blood...
In early December, CRISPR-Cas9 gene editing therapy was approved by the Food and Drug Administration for the treatment of sickle cell in patients ages 12 and up. It’s the first FDA approval for the gene-editing therapy, whose creators won the Nobel Prize in chemistry in 2020.
NJ-based Atlantic Health System is the first in the U.S. to enroll a patient in a study to examine the effectiveness of using Chimeric Antigen Receptor (CAR- T)
TriStar Centennial doctor led national CRISPR clinical trial